OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance

Core Insights - OrthoPediatrics Corp. achieved record full year 2024 revenue of $205 million, reflecting a 38% year-over-year growth compared to $148.7 million in 2023 [1][6] - The company projects 2025 revenue to be between $235 million and $242 million, indicating a growth of 15% to 18% compared to 2024 [3] - OrthoPediatrics expects to generate adjusted EBITDA of $15 million to $17 million for the full year 2025 [3] 2024 Business and Financial Highlights - The company helped over 34,000 children in Q4 2024, totaling over 1.1 million children since inception [6] - Preliminary unaudited Q4 2024 net revenue reached $52.7 million, a 40% increase from $37.6 million in Q4 2023 [6] - Domestic Q4 2024 net revenue is expected to be $42.9 million, representing a 52% growth year-over-year, while international net revenue is projected at $9.8 million, a 5% increase [6] Strategic Initiatives - The Trauma and Deformity and Scoliosis businesses are key contributors to the company's growth, with a strong performance in the specialty bracing (OPSB) business [4] - The company aims to expand and scale its OPSB business, viewing it as a significant market opportunity and a strategic catalyst for growth [4] - OrthoPediatrics plans to release detailed Q4 and full year 2024 financial results in early March, with preliminary figures subject to adjustment [4]